G. Demonty

发表

Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma

M. Peeters, A. Zaniboni, M. Valladares-Ayerbes, 2018, ESMO Open.

Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status

C. Köhne, M. Peeters, F. Rivera, 2017, Clinical colorectal cancer.

Panitumumab‐based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials

J. Douillard, F. Rivera, J. Bachet, 2019, International journal of cancer.

Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma

J. Hecht, G. Fasola, J. Canon, 2017, International Journal of Colorectal Disease.

Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial

J. Tabernero, J. Canon, G. Bodoky, 2016, ESMO Open.

European follow-up of incorrect biomarker results for colorectal cancer demonstrates the importance of quality improvement projects

C. Keppens, E. Dequeker, G. Kafatos, 2019, Virchows Archiv.

PACS 01 trial: questions about patients' characteristics and reported results.

J. Bogaerts, G. Demonty, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals

M. Schiødt, S. Otto, T. Van den Wyngaert, 2020, Supportive Care in Cancer.

Charting Recent Progress and Challenges in Metastatic Castration-resistant Prostate Cancer: Is There an Optimal Treatment Sequence?

S. Oudard, W. Gerritsen, P. Maroto, 2016, European urology focus.

2014 Final analysis of the PEAK trial: Overall survival (OS) and tumour responses during first-line treatment with mFOLFOX6 + either panitumumab (pmab) or bevacizumab (bev) in patients (pts) with metastatic colorectal carcinoma (mCRC)

J. Hecht, G. Fasola, J. Canon, 2015 .

Characteristics and response outcomes of long-term survivors in studies of first-line panitumumab for metastatic colorectal cancer.

A. Carrato, C. Köhne, M. Peeters, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

P-149Impact of sequence of biologic therapies on overall survival (OS) in patients with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC): an exploratory, retrospective pooled analysis

J. Douillard, M. Valladares-Ayerbes, F. Rivera, 2016 .

PD-014First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in patients with RAS/BRAF wild-type (WT) metastatic colorectal carcinoma (mCRC)

J. Hecht, G. Fasola, J. Canon, 2015 .

Treatment guidelines for adjuvant breast cancer are moving toward double standards: one for the rich and one for the poor.

G. Demonty, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Healthcare Professionals’ Perspective on Impact and Actions Taken Following Severe Infusion Reaction Events in Oncology Centers in Europe

S. Dube, G. Kafatos, K. Lowe, 2020, Drugs - Real World Outcomes.

Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors.

R. Hofheinz, S. Segaert, H. Prenen, 2017, Critical reviews in oncology/hematology.

'Pure' invasive apocrine carcinoma of the breast: a new clinicopathological entity?

E. G. Deza, F. G. Gercovich, G. Demonty, 2005, Breast.

Adjuvant chemotherapy in 2005: standards and beyond.

M. Piccart, T. Čufer, E. de Azambuja, 2005, Breast.

Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer.

E. Rutgers, R. Mansel, J. Bogaerts, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Critical Reviews in Oncology/Hematology Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases

J. Body, Aliki Taylor, J. Amelio, 2022 .

Docetaxel Plus Trastuzumab as Treatment for Her-2 Positive Metastatic Breast Cancer: Review of the Existing Evidence

G. Demonty, 2007, Women's health.

Progress and new standards of care in the management of HER-2 positive breast cancer.

M. Piccart, F. Puglisi, I. Mancini, 2007, European journal of cancer.

Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials

M. Peeters, M. Valladares-Ayerbes, F. Rivera, 2017, Journal of Cancer Research and Clinical Oncology.

Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials.

U. Dafni, R. Stahel, M. Guillot, 2021, Lung cancer.

Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study

P. Gibbs, Tae Won Kim, P. Ruff, 2018, Clinical Cancer Research.

Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer--Gynaecological Cancer Group).

I. Vergote, P. Witteveen, C. Coens, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients' Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology Centers.

S. Segaert, S. Dube, G. Kafatos, 2020, Clinical colorectal cancer.

Shrinking the tumor, shrinking the patient sample size: the early disclosure dilemma.

F. Puglisi, E. de Azambuja, G. de Castro, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review

J. Trojan, P. Fabián, L. Mineur, 2017, BMC Cancer.

Genomic and molecular classification of breast cancer

C. Sotiriou, E. Liu, S. Loi, 2006 .

Author Correction: Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials

M. Peeters, M. Valladares-Ayerbes, F. Rivera, 2018, Journal of Cancer Research and Clinical Oncology.

PD-031An exploratory study-level meta-analysis assessing the impact of early tumour shrinkage on overall survival in patients with RAS wild-type metastatic colorectal cancer receiving first-line treatment in three randomised panitumumab trials

J. Douillard, M. Valladares-Ayerbes, F. Rivera, 2016 .

Primary tumor sidedness impacts on prognosis and treatment outcome: results from three randomized studies of panitumumab plus chemotherapy versus chemotherapy or chemotherapy plus bevacizumab in 1st and 2nd line RAS/BRAF WT mCRC

C. Rolfo, M. Peeters, G. Kafatos, 2016 .

I. Vergote, P. Witteveen, C. Coens, 2009, Annals of Oncology.

Charting Recent Progress and Challenges in Metastatic Castration-resistant Prostate Cancer: Is There an Optimal Treatment Sequence?

S. Oudard, W. Gerritsen, P. Maroto, 2016, European urology focus.

Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC

T. Buchler, M. Kiehl, H. Hebart, 2019, Advances in Therapy.